Tuesday, June 3, 2025
The Lagos Today
  • Login
No Result
View All Result
No Result
View All Result
The Lagos Today
No Result
View All Result
Home Biotech

Spero Therapeutics’ Antibiotic Setback Leads to Major Workforce Cut

by Iyanu Ale
October 30, 2024
in Biotech
Reading Time: 2 mins read
0
0
Spero Therapeutics’ Antibiotic Setback Leads to Major Workforce Cut
Share on FacebookShare on Twitter

Spero Therapeutics is facing a significant setback after its oral antibiotic candidate, SPR720, failed to show effectiveness in a recent phase 2a trial and raised safety concerns. The disappointing results prompted the company to lay off 39% of its workforce to extend its cash reserves through mid-2026.

SPR720, which Spero acquired from Vertex in 2016 for an initial payment of $500,000, was designed as an oral treatment option for nontuberculous mycobacterial (NTM) pulmonary disease, a condition typically requiring lengthy and complex combination therapies. Spero’s candidate aimed to simplify this process with an oral alternative; however, the recent interim analysis showed that SPR720 not only failed to outperform a placebo but also presented dose-limiting safety issues, including three cases of reversible grade 3 liver toxicity at a 1,000 mg dose. This double blow led Spero to pause development of the drug while they assess further options.

SPR720 operates with a different mechanism than existing treatments like Insmed’s Arikayce, which is used in combination therapies for NTM infections. Spero had hoped this new approach would limit drug resistance, but the poor trial results and safety concerns have cast doubt on SPR720’s viability. This setback follows similar issues in the field, including a recent failure by AN2 Therapeutics.

The setback has led Spero to implement significant restructuring, marking the second major layoff for the company in recent years. In 2022, after the FDA rejected Spero’s application for its oral antibiotic tebipenem HBr—a candidate with potential to treat complicated urinary tract infections—the company cut 75% of its workforce, reducing its staff from 146 to just 41. Tebipenem’s failure caught the attention of GSK, which stepped in with a $66 million investment to support a new phase 3 trial, expected to complete enrollment by late 2025.

For now, Spero’s remaining team will focus on advancing tebipenem HBr and exploring options for SPR206, another antibiotic candidate targeting multidrug-resistant Gram-negative pathogens, contingent upon securing additional funding.

Share this:

  • Facebook
  • X

Like this:

Like Loading...
Tags: AntibioticsSperoSpero TherapeuticsTherapeutics
Previous Post

GSK Shifts Strategy, Axes Adult Vaccine Candidate in $2.1B Affinivax Deal Amid Rising Competition

Next Post

Archon Biosciences Emerges from Stealth with $20M Funding to Create ‘Antibody Cages’

Iyanu Ale

Iyanu Ale

Related Posts

Biotech Innovator Lykos Forges Ahead with Groundbreaking MDMA Treatment

by Iyanu Ale
January 17, 2025
0

Lykos, a biotech company, has been making headlines with its innovative approach to treating post-traumatic stress disorder (PTSD). The company's...

Biotech Breakthrough Verdiva Raises $410M to Revolutionize Obesity Treatment with Game-Changing Weight Loss Drug

Biotech Breakthrough Verdiva Raises $410M to Revolutionize Obesity Treatment with Game-Changing Weight Loss Drug

by Iyanu Ale
January 9, 2025
0

Verdiva, a biotechnology company, has burst onto the scene with a staggering $410 million Series A funding round. This monumental...

Next Post
Archon Biosciences Emerges from Stealth with $20M Funding to Create ‘Antibody Cages’

Archon Biosciences Emerges from Stealth with $20M Funding to Create ‘Antibody Cages’

Please login to join discussion

Recommended

#EndSARS: Lagos CP Mourns the Murder of Six Officers During Unrest

Covid-19: Lagos CP Redeploys Ajao Estate DPO For Aiding Protocols Violation

4 years ago
FG Suspends NIMC Officials in Bauchi, Kaduna For Extorting Applicants

NIN: FG Threatens 14-yr Jail Term for Defaulters

4 years ago

Popular News

    Connect with us

    Tags

    #EndSARS 2023 Elections 2023 polls 2023 Presidency ACCIDENT Africa All progressives Congress APC Asiwaju Bola Tinubu Babajide Sanwo-Olu CBN Central Bank of NIgeria Central Bank of Nigeria (CBN) Coronavirus pandemic Covid-19 Covid-19 in Lagos Covid-19 in Nigeria Covid-19 Vaccine Cryptocurrency Economic and Financial Crimes Commission EFCC Federal Government Federal Government of Nigeria Fraud Gov. Sanwo-Olu House of Representatives Lagos-Ibadan expressway Lagos state Lagos State Government Lagos State House of Assembly Lagos State Police command Muhammadu Buhari Murder Naira NDLEA Nigeria Nigeria Customs Service Nigerian Economy Nigeria Police Force Rape Strike action TECH UK United Kingdom US

    News

    Opinion

    © 2020 The Lagos Today - Nkali.

    Welcome Back!

    Login to your account below

    Forgotten Password?

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In
    No Result
    View All Result

    © 2020 The Lagos Today - Nkali.

    %d